they mean broader category coverage and more variables to interpret
On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
Anything earlier would require priority review, which is possible but not the default for obesity
That moat just lost its first major brick
doi: 10.1530/EC-23-0005 PMID: 37159343 Pronunciation: kan-a-gli-FLOE-zin Dapagliflozin (Farxiga ) Trade Names: Farxiga (Forxiga in Europe) Drug Class: Anti-diabetic drug, Hypoglycemic, SGLT-2 inhibitor, Gliflozin Pharmacology is similar to canagliflozin, the other SGLT-2 inhibitor in this drug class Mechanism of Action: Hypoglycemic : Inhibits the Na-glucose co-transporter 2 (SGLT-2) in the kidney to reduce glucose reabsorption, resulting in increased urinary glucose excretion, and lower plasma glucose
No, not for weight loss alone
